加载中
NASDAQHealthcareBiotechnology
最新数据
US$17.77
+US$1.24 · +7.50%
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.
收盘时
US$17.77
+US$1.24 · +7.50%
盘后
US$17.6171
−US$0.1529 · -0.86%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.
日内区间
当前US$17.77
52周区间
当前US$17.77
盘中时间采用ET。市场数据可能有所延迟。
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.
日内区间
当前US$17.77
52周区间
当前US$17.77
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 1779 USD | 3612 USD | 3612 USD | 3612 USD | 3612 USD |
| 毛利 | −1779 USD | −3612 USD | −3612 USD | −3612 USD | −3612 USD |
| 研究与开发 | 1722.04万 USD | 1548.02万 USD | 769.86万 USD | 647.57万 USD | 355.95万 USD |
| 销售、一般及管理费用 | 222.57万 USD | 215.34万 USD | 162.92万 USD | 156.46万 USD | 103.84万 USD |
| 营业费用 | 1944.61万 USD | 1763.36万 USD | 932.43万 USD | 803.66万 USD | 459.43万 USD |
| 利息收入 | 8.97万 USD | 22.3万 USD | 43.61万 USD | 21.5万 USD | 2.74万 USD |
| 折旧和摊销 | 1779 USD | 3612 USD | 3612 USD | 3612 USD | 3612 USD |
| 营业利润 | −1944.79万 USD | −1763.72万 USD | −932.79万 USD | −804.03万 USD | −459.79万 USD |
| 净利润 | −1935.82万 USD | −1741.42万 USD | −889.18万 USD | −782.52万 USD | −457.06万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$50.00
上涨空间 181.37%报告持有此股票敞口的交易所交易基金。
iShares Russell 2000 ETFIWM334.96万0.00%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Morningstar Total Stock Market ETFVTI297.53万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 Growth ETFIWO118.96万0.01%139.17亿 USD0.24%US$353.71-0.86%
Vanguard Extended Market ETFVXF108.04万0.00%954亿 USD0.05%US$233.52-0.63%
Vanguard U.S. Momentum Factor ETFVFMO80.4万0.04%19亿 USD0.13%US$227.71-1.04%
Vanguard Russell 2000 ETFVTWO57.75万0.00%180亿 USD0.06%US$112.27-0.35%
iShares Micro-Cap ETFIWC40.67万0.03%13.17亿 USD0.60%US$181.66-0.73%
Vanguard Russell 2000 Growth ETFVTWG11.21万0.01%17亿 USD0.06%US$258.28-0.85%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFVanguard U.S. Momentum Factor ETFVFMOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
